AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

Clinical trial NCT06320717 · RECRUITING

Trial details

NCT number: NCT06320717
Sponsor: Roswell Park Cancer Institute
Status: RECRUITING
Study type: OBSERVATIONAL

Pancreatic Ductal Adenocarcinoma

Start date: 2024-01-02
Primary completion: 2026-12-02
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.